Pharmaceutical Literacy and Quality of Life in Spanish Population.
Launched by UNIVERSITY OF BARCELONA · Dec 9, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
A cross-sectional study is carried out, consisting of an interview between the patients and community pharmacists included in the study.
The participants selected are adults usually taking medication that answer questions related to their pharmaceutical literacy (RALPH interview). This type of literacy refers to three domains regarding functional, comunicative and critical abilities about their own medication.
After that, every participant answers a simple survey regarding their health-related quality of life including topics such as mobility, self-care, everyday activities, pain and ment...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults currently taking at least one medication prescribed by a physician and living in Spain.
- Exclusion Criteria:
- • Having physical or cognitive limitations that make it impossible to answer the study questions.
About University Of Barcelona
The University of Barcelona, a prestigious institution renowned for its commitment to research and academic excellence, serves as a leading sponsor for clinical trials aimed at advancing medical knowledge and improving patient outcomes. With a rich history of innovation and collaboration, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research across various fields, including medicine, pharmacology, and public health. Through its robust network of partnerships with healthcare providers and research organizations, the University of Barcelona is dedicated to fostering advancements in clinical practice and contributing to the development of effective therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Trial Officials
Pilar Modamio Charles, PhD
Study Director
University of Barcelona
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported